[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Asavamongkolkul A, Pimolsanti R, Waikakul S, Kiatsevee P: Periacetabular limb salvage for malignant bone tumours. J Orthop Surg (Hong Kong); 2005 Dec;13(3):273-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periacetabular limb salvage for malignant bone tumours.
  • PURPOSE: To evaluate treatment outcomes in primary malignant periacetabular bone tumour removal and limb salvage with or without bone-graft reconstruction.
  • METHODS: A total of 13 patients were treated for malignant periacetabular bone tumours at Siriraj Hospital, Bangkok, Thailand.
  • The diagnoses were chondrosarcoma (n=8), Ewing's sarcoma (n=2), osteosarcoma (n=1), well-differentiated osteosarcoma (n=1), and malignant giant cell tumour (n=1).
  • 11 patients did not undergo reconstruction following tumour resection; 2 patients received fibular bone grafts bridging the periacetabulum to the remaining sacrum.
  • Adjuvant chemotherapy was administered for high-grade malignant tumours, and postoperative radiation therapy was performed on patients with a closed surgical margin.
  • According to the Musculoskeletal Tumor Society classification system, the mean functional analysis at final follow-up was 68.7%.
  • CONCLUSION: Malignant periacetabular tumours are difficult to manage.
  • [MeSH-major] Bone Neoplasms / therapy. Limb Salvage. Pelvic Bones
  • [MeSH-minor] Adult. Bone Transplantation. Chemotherapy, Adjuvant. Child. Chondrosarcoma / therapy. Combined Modality Therapy. Disease-Free Survival. Female. Giant Cell Tumor of Bone / therapy. Humans. Male. Middle Aged. Osteosarcoma / therapy. Sarcoma, Ewing / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365491.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Shi SF, Dong Y, Zhang CL, Bao K, Ma XJ: [Prosthesis replacement of the proximal humerus after the resection of bone tumors]. Chin J Cancer; 2010 Jan;29(1):121-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: After chemotherapy was used to treat patients with malignant bone tumors in 1970s, amputation, which was the typical intervention in the 1980s, has been substituted with limb-sparing surgery.
  • METHODS: From April 2004 and December 2008, prosthetic replacement was performed in 18 patients with proximal humerus tumors, including 7 patients with osteosarcoma, 5 patients with chondrosarcoma, 3 patients with giant cell tumor (GCT) of the bone, 1 patient with GCT of the bone combined with an aneurysmal bone cyst, and 1 patient with metastatic bone tumors.
  • According to the functional score developed by the International Society of Limb Salvage, scores ranged between 18 and 29 points, with an average of 24 points.
  • CONCLUSIONS: The prosthesis replacement for the patients with bone tumors in the proximal humerus is an appropriate procedure with satisfactory therapeutic outcomes; however, many complications should be noted and long-term therapeutic effect needs further investigations.
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement. Female. Follow-Up Studies. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / radiography. Giant Cell Tumor of Bone / surgery. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Range of Motion, Articular. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038324.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Théoleyre S, Mori K, Cherrier B, Passuti N, Gouin F, Rédini F, Heymann D: Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer; 2005;5:123
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma.
  • BACKGROUND: Osteosarcoma is the most common type of primary bone tumor.
  • The use of aggressive chemotherapy has drastically improved the prognosis of the patients with non-metastatic osteosarcomas, however the prognosis of the patients with metastasis is still very poor.
  • Then, new and more effective treatments for curing osteosarcoma, such as immunotherapy are needed.
  • Tumor-infiltrating lymphocytes (TIL) have been involved in the control of tumor development and already assessed with success for the treatment of several cancers including melanoma.
  • While TIL represent a fascinating therapeutic approach in numerous malignant pathologies, there is few report concerning adult bone-associated tumors including osteosarcoma.
  • METHODS: Human TIL were isolated and characterized (phenotype, lytic activity) from twenty-seven patients with bone-associated tumors (osteosarcoma, Ewing's sarcoma, giant cell tumor, chondrosarcoma, plasmocytoma and bone metastases).
  • RESULTS: While TIL with a main CD4+ profile were easily isolated from most of the tumor samples, only TIL extracted from osteosarcoma were cytotoxic against allogeneic tumor cells.
  • Similar data were observed in rat osteosarcoma model where TIL were characterized by a main CD4+ profile and high lytic activity against allogeneic and autologous tumor cells.
  • Moreover, rat TIL expansion was not accompanied by refractoriness to further activation stimulus mainly by tumor antigens.
  • CONCLUSION: These results demonstrated that TIL therapy could be a very efficient strategy for the treatment of adult osteosarcoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. CD4-Positive T-Lymphocytes / cytology. Cell Line, Tumor. Disease Models, Animal. Female. Flow Cytometry. Humans. Immunotherapy / methods. Leukocytes / pathology. Lymphocytes, Tumor-Infiltrating / cytology. Male. Melanoma / pathology. Middle Aged. Neoplasm Metastasis. Phenotype. Prognosis. Rats

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1999 Nov;12(11):1050-6 [10574602.001]
  • [Cites] Cancer Immunol Immunother. 2006 Apr;55(4):451-8 [16034562.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):29-32 [10853014.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Jul-Aug;17(5):355-64 [10914045.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] J Orthop Res. 2001 May;19(3):346-51 [11398844.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):963-70 [11549589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70 [11734652.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3950-62 [11751487.001]
  • [Cites] Cancer Immunol Immunother. 2002 Nov;51(10):539-46 [12384805.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):332-42 [12843795.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):53-7 [14736523.001]
  • [Cites] Intern Med. 2004 Apr;43(4):323-6 [15168777.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5442-8 [15289353.001]
  • [Cites] Cancer. 1976 Jan;37(1):1-11 [1082364.001]
  • [Cites] Int J Cancer. 1977 Jul 15;20(1):112-9 [269099.001]
  • [Cites] Science. 1986 Sep 19;233(4770):1318-21 [3489291.001]
  • [Cites] J Biol Response Mod. 1990 Apr;9(2):149-59 [1971302.001]
  • [Cites] Eur J Immunol. 1991 Jun;21(6):1403-10 [1904359.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 3;83(13):932-7 [2067036.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):8-14 [1884563.001]
  • [Cites] Cancer Immunol Immunother. 1992;34(4):241-51 [1311218.001]
  • [Cites] Cancer Immunol Immunother. 1994 May;38(5):332-8 [8162615.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66 [8028037.001]
  • [Cites] Immunol Rev. 1995 Jun;145:167-77 [7590825.001]
  • [Cites] Ann Surg Oncol. 1996 Nov;3(6):580-7 [8915492.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] J Orthop Res. 1997 Jan;15(1):128-32 [9066537.001]
  • [Cites] Br J Urol. 1997 Oct;80(4):543-7 [9352689.001]
  • [Cites] Pathol Res Pract. 1998;194(10):679-84 [9820863.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):1137-42 [10368665.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):721-6 [10505031.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):730-7 [15665620.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):2026-34 [15753403.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):779-91 [15753211.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2457-64 [15781662.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):258-67 [15838383.001]
  • [Cites] J Immunol. 2005 May 15;174(10):5959-67 [15879088.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3998-4004 [15899788.001]
  • [Cites] Bone. 2005 Jul;37(1):74-86 [15894525.001]
  • [Cites] Eur J Immunol. 2005 Jun;35(6):1754-63 [15902685.001]
  • [Cites] Oncol Rep. 2005 Sep;14(3):763-9 [16077989.001]
  • [Cites] Tumori. 2000 Jan-Feb;86(1):46-52 [10778766.001]
  • (PMID = 16188028.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1262697
  •  go-up   go-down


Advertisement
4. Bertoni F, Bacchini P, Staals EL: Malignancy in giant cell tumor. Skeletal Radiol; 2003 Mar;32(3):143-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancy in giant cell tumor.
  • Malignant giant cell tumor is a confusing term that in the past has been used to describe different types of giant cell-rich tumors.
  • We consider two types of malignancy in giant cell tumor of bone: "primary" when it arises in juxtaposition to a benign giant cell tumor and 'secondary' when it arises at the site of a previously treated giant cell tumor.
  • Here we present a case of primary malignancy in giant cell tumor that was initially not recognized as a malignancy.
  • On radiography and histology of frozen sections the lesion had the appearance of a conventional giant cell tumor of bone.
  • After curettage, the permanent histology slides showed areas of highly malignant osteosarcoma juxtaposed to areas of benign giant cell tumor.
  • The patient was treated with chemotherapy and wide resection of the tumor.
  • [MeSH-major] Femoral Neoplasms / pathology. Giant Cell Tumor of Bone / pathology. Osteosarcoma / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12605278.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Guo W, Tang XD, Li X, Ji T, Sun X: [The analysis of the treatment of giant cell tumor of the pelvis and sacrum]. Zhonghua Wai Ke Za Zhi; 2008 Apr 1;46(7):501-5
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The analysis of the treatment of giant cell tumor of the pelvis and sacrum].
  • OBJECTIVE: To discuss the surgical management, local recurrence rate and complications of giant cell tumor (GCTs) of the pelvic and sacrum.
  • Surgical management: 2 patients received 3 times of operations and 7 underwent 2 operations.
  • There were 19 patients managed with intralesional marginal excision and 2 patients with intralesional marginal excision and adjuvant radiotherapy, another 3 patients with widely marginal excision as the treatment of sacral lesions.
  • RESULTS: One recurrent patient with the large, ragged tumor died of serious infection in 2 weeks after the second surgery.
  • One patient of malignant giant cell tumor of sacrum died at 15 months after surgery.
  • One patient with sacral lesion occurred pulmonary metastases in two years after surgery, and received chemotherapy with ADM, DDP and IFO.
  • One year later there was no much change in metastatic tumor.
  • CONCLUSIONS: The treatment for GCT of the pelvic and sacrum should be more aggressive because of high incidence of local recurrence after intralesional excision.
  • Although it might induce sacral nerve deficit, widely marginal excision is the best surgical procedure because of its low recurrence rate.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Pelvic Bones. Sacrum

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785558.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Alacacioğlu A, Bengi G, Oztop I, Canda T, Balci P, Osma E, Yilmaz U: Metastasis of giant cell tumor to the breast: case report and review of the literature. Tumori; 2006 Jul-Aug;92(4):351-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of giant cell tumor to the breast: case report and review of the literature.
  • Breast cancer is the most common type of malignancy in women.
  • Metastasis of soft tissue tumors to the breast is rarely seen.
  • In particular, metastasis of a giant cell tumor to the breast has never been reported in the literature.
  • We present here a case of breast metastasis in a 44-year-old woman with a diagnosis of malignant giant cell tumor originating from the distal radius and metastatic to the lung, who had been treated with radiotherapy, surgery and chemotherapy.
  • [MeSH-major] Bone Neoplasms / pathology. Breast Neoplasms / secondary. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Radius
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Mammography. Mastectomy, Segmental. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036529.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


7. Pan YW, Huang XY, You JF, Tian GL, Li C: [Malignant giant cell tumor of the tendon sheaths in the hand]. Zhonghua Wai Ke Za Zhi; 2008 Nov 1;46(21):1645-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant giant cell tumor of the tendon sheaths in the hand].
  • OBJECTIVES: To retrospectively study on malignant giant cell tumor of tendon sheath (MGCTTS) in the hand, and to evaluate its clinical, histologic, immunohistochemical features and biologic evolution.
  • Immunohistochemical studies and nuclear suspensions for flow cytometry were done on paraffin embedded tissue.
  • RESULTS: Three of 10 patients in which the diagnosis of MGCTTS was originally considered were excluded after the slides reviewed and immunohistochemical examination performed.
  • In the other 7 patients, one showed malignant and aggressive nature: the lesion recurred several times and the patient eventually died with pulmonary metastases.
  • None of them had received chemotherapy or radiation therapy.
  • CONCLUSIONS: Malignant giant cell tumor of tendon sheath is an extremely rare malignant tumor, some cases have a poor outcome, the others, despite the histologically malignant features, have a good prognosis if wide surgical excision ablates the tumor completely.
  • [MeSH-major] Giant Cell Tumors / pathology. Hand / pathology. Tendons / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094761.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


8. Dodd LG, Major N, Brigman B: Malignant giant cell tumor of soft parts. Skeletal Radiol; 2004 May;33(5):295-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant giant cell tumor of soft parts.
  • Giant cell tumor of soft parts (GCTSP) is an extremely rare lesion with an unpredictable behavior.
  • Some patients are cured with a simple surgical excision whereas others will develop metastatic disease within a relatively short interval.
  • We describe the clinical, histologic and radiologic features of a case with malignant behavior.
  • The patient presented with a fungating skin and soft tissue mass and concurrent pulmonary nodules.
  • [MeSH-major] Giant Cell Tumors / pathology. Leg / pathology. Lung Neoplasms / diagnosis. Osteosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Biopsy / methods. Diagnosis, Differential. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases / drug therapy. Rare Diseases / pathology. Rare Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):248-56 [10680893.001]
  • [Cites] J Pathol. 1972 May;107(1):27-39 [4262633.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):736-47 [7226022.001]
  • [Cites] Cancer. 1972 Jun;29(6):1518-29 [5031245.001]
  • [Cites] Am J Dermatopathol. 1989 Jun;11(3):197-201 [2658646.001]
  • [Cites] Mod Pathol. 1999 Sep;12 (9):894-902 [10496598.001]
  • [Cites] Am J Surg. 1978 Jul;136(1):102-6 [277073.001]
  • [Cites] Cancer. 1977 Jul;40(1):244-53 [195704.001]
  • (PMID = 14997349.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Lachat MR, Weber M, Cserhati MD, Honegger HP, von Hochstetter AR: [Giant cell tumor of bone with rapid malignant course]. Orthopade; 2004 Mar;33(3):344-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumor of bone with rapid malignant course].
  • [Transliterated title] Riesenzelltumor des Knochens mit rapid malignem Verlauf.
  • The case of a 28-year-old male patient with a locally aggressive lesion of the distal tibia is presented.
  • Following the diagnosis of giant cell tumor of bone (GCT) on biopsy and curettage, a rapid malignant course was observed with recurrence 2.5 months later.
  • Following initial chemotherapy according to the COSS protocol and later with carboplatin and VP-16, therapy was changed to Adriamycin and later gemcitabine due to progressive disease.
  • The malignant nature of the tumor was not detected in the initial pathologic examinations.
  • Review of the pathologic material provided histologic clues permitting the diagnosis of a primary malignant GCT with a fibrohistiocytic/fibrosarcomatous component.
  • Malignancy in a giant cell tumor is a much debated diagnostic dilemma when a frank sarcomatous component is lacking.
  • Cytologic atypias and flame-like tufts of infiltration of soft tissue are important clues.
  • Surgical treatment should be commensurate.
  • [MeSH-major] Ankle Joint. Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Tibia
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Transplantation. Curettage. Disease Progression. Fatal Outcome. Humans. Lung / pathology. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Reoperation. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1985 Jul;67(6):890-900 [4019539.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1244-55 [3855683.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):104-8 [11310196.001]
  • [Cites] J Bone Joint Surg Am. 1997 Feb;79(2):259-62 [9052550.001]
  • [Cites] Mod Pathol. 1989 Sep;2(5):541-6 [2554283.001]
  • [Cites] Cancer. 1979 Oct;44(4):1393-402 [227563.001]
  • [Cites] J Bone Joint Surg Am. 1992 Jul;74(6):930-4 [1634584.001]
  • [Cites] J Bone Joint Surg Am. 1989 Jun;71(5):757-61 [2732265.001]
  • [Cites] Clin Orthop Relat Res. 2000 Dec;(381):185-91 [11127655.001]
  • [Cites] J Bone Joint Surg Br. 1972 May;54(2):216-29 [5034822.001]
  • [Cites] Skeletal Radiol. 1997 Apr;26(4):246-55 [9151375.001]
  • [Cites] AJR Am J Roentgenol. 1985 May;144(5):955-60 [3872579.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • (PMID = 15007559.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Xu J, Sun H, Xiao Y: [Application of medial head gastrocnemius muscle flap to limb-salvage operation of proximal tibial malignant tumor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Apr;21(4):352-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of medial head gastrocnemius muscle flap to limb-salvage operation of proximal tibial malignant tumor].
  • METHODS: From January 2001 to September 2005, 13 patients (8 males, 5 females; aged 14-57 years, averaged 29.7 years) suffering from the proximal tibial tumors were treated with a limb-salvage operation.
  • Among them, there were 4 patients with osteosarcoma, 6 with malignant fibrous histocytoma, 1 with malignant giant cell tumor, 1 with synovial sarcoma, and 1 with Ewing's sarcoma.
  • One or two cycles of neoadjuvant chemotherapy were used to each of the patients before operation.
  • All of the patients underwent the medial head of the gastrocnemius muscle flap transposition to reconstruct the soft tissues after resection of the tumors and reconstruction of the bone defect by prothesis or bone-graft or the two methods combined.
  • The patient with malignant fibrous histocytoma died of systemic metastasis 20 months after operation.
  • The patient with Ewing's sarcoma had a local tumor recurrence 18 months after operation; though treated with the focal cleaning and the bone cement filling, the patient still developed lung metastasis of the tumor 26 months after operation.
  • The patient with osteosarcoma underwent amputation 12 months after operation because of the tumor recurrence.
  • According to the function assessment by the Mankin system, there were 6 patients who had an excellent result, 4 had a good result, and 3 had a poor result, with a satisfaction rate of 77%.
  • CONCLUSION: The flap transposition of the medial head of the gastrocnemius muscle can reconstruct the soft tissue defect, decrease the local complication rate and improve the clinical outcome of the limb salvage for the proximal tibia malignant tumor.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage / methods. Osteosarcoma / surgery. Soft Tissue Injuries / surgery. Surgical Flaps / blood supply. Tibia
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement, Knee. Bone Transplantation / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546876.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Bouralexis S, Clayer M, Atkins GJ, Labrinidis A, Hay S, Graves S, Findlay DM, Evdokiou A: Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin. Int J Oncol; 2004 May;24(5):1263-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin.
  • Chemotherapy is an established treatment modality for bone sarcomas such as osteosarcoma (OS).
  • However, the use of chemotherapy in high-grade soft tissue sarcomas remains controversial, with the most active chemotherapeutic agent, doxorubicin (DOX), reported to have a response rate of, at best only 34% and most studies reporting lower response rates.
  • Apo2L/TRAIL is a member of the tumour necrosis factor (TNF) family of cytokines and induces death of tumour cells, but not normal cells.
  • Its potent apoptotic activity is mediated through cell surface death domain-containing receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2.
  • We investigated the efficacy of Apo2L/TRAIL as a single agent, and in combination with clinically relevant chemotherapeutic drugs, in fresh isolates of primary malignant cells obtained from biopsy material.
  • The data presented here demonstrate that, in a range of primary bone related tumours, as well as soft tissue sarcomas, chemotherapeutic agents were only moderately effective, in terms of induction of cell death.
  • Apo2L/TRAIL alone had little or no effect on any bone-related tumour or sarcoma in culture.
  • In contrast, the combination of Apo2L/TRAIL and chemotherapeutic drugs produced a significant increase in tumour cell death, with DOX and Apo2L/TRAIL proving to be the most effective combination.
  • These data suggest the potential for Apo2L/TRAIL to increase the effectiveness of chemotherapeutic drugs in bone and soft tissue sarcomas, while perhaps concurrently allowing a reduction in the exposure to drugs such as DOX, and a consequent reduction in toxicity.
  • The synergistic action between these two different classes of agents has yet to be tested in vivo but may prove clinically relevant in the treatment of this refractive class of malignancies.
  • [MeSH-major] Bone Neoplasms / drug therapy. Doxorubicin / therapeutic use. Giant Cell Tumor of Bone / therapy. Membrane Glycoproteins / therapeutic use. Osteosarcoma / drug therapy. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins. Child. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. TNF-Related Apoptosis-Inducing Ligand. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15067350.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Membrane Glycoproteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin
  •  go-up   go-down


12. Kawamura S, Nakamura T, Oya T, Ishizawa S, Sakai Y, Tanaka T, Saito S, Fukuoka J: Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int; 2007 Apr;57(4):213-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy.
  • Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm that is benign in most cases.
  • Herein is reported a case of a 74-year-old woman with a giant malignant SFT in the pelvis.
  • Along with massive invasion to adjacent organs and multiple lung metastases detected on radiography, biopsy from the tumor through the vaginal wall showed malignant looking spindle-cell neoplasm with increased cellularity, areas of necrosis, and high mitotic activity (5/10 high-power fields).
  • Immunohistochemically, the tumor cells were diffusely and strongly positive for CD34, CD99, and bcl-2.
  • Based on pathological features and clinical presentation, diagnosis of malignant SFT was made.
  • The patient received systemic and the intra-arterial chemotherapy followed by whole pelvic radiation therapy (50 Gy).
  • Initial chemotherapies failed to control the tumor.
  • Afterwards, improvement was observed radiologically and pathologically in the 12 months' follow up after the radiation therapy.
  • This is the first report related to therapeutic remarks on advanced malignant SFT.
  • [MeSH-major] Carcinoma / radiotherapy. Neoplasms, Fibrous Tissue / radiotherapy. Pelvic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316417.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


13. Hsieh PC, Li KW, Sciubba DM, Suk I, Wolinsky JP, Gokaslan ZL: Posterior-only approach for total en bloc spondylectomy for malignant primary spinal neoplasms: anatomic considerations and operative nuances. Neurosurgery; 2009 Dec;65(6 Suppl):173-81; discussion 181
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior-only approach for total en bloc spondylectomy for malignant primary spinal neoplasms: anatomic considerations and operative nuances.
  • MALIGNANT PRIMARY SPINAL tumors are rare tumors that are locally invasive and can metastasize.
  • The majority of these tumors have a poor response rate to chemotherapy and conventional radiotherapy.
  • Total en bloc spondylectomy involves removal of vertebral segment(s) in whole to achieve wide tumor excision.
  • The posterior-only approach offers the advantage of achieving complete tumor excision and circumferential spinal reconstruction in a single setting.
  • In this report, we discuss the operative management of malignant primary vertebral tumors using the posterior-only approach for total en bloc spondylectomy.
  • [MeSH-minor] Adult. Arthrodesis / instrumentation. Arthrodesis / methods. Diskectomy / instrumentation. Diskectomy / methods. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / radiography. Giant Cell Tumor of Bone / surgery. Humans. Laminectomy / instrumentation. Laminectomy / methods. Male. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934992.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


14. Wang BG, Liang H, Cui QH, Wang JC, Liu JZ: [Malignant fibrous histiocytoma of the retroperitoneum: an analysis of 31 cases]. Zhonghua Zhong Liu Za Zhi; 2004 Jun;26(6):373-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant fibrous histiocytoma of the retroperitoneum: an analysis of 31 cases].
  • OBJECTIVE: To investigate the diagnosis and treatment of malignant fibrous histiocytoma of the retroperitoneum (MFHR).
  • METHODS: The clinicopathological features, treatment and prognosis of 31 patients with MFHR were retrospectively analyzed.
  • The average diameter of tumor was 15 cm.
  • The histopathologic types of the tumor were inflammatory, storiform-pleomorphic, myxoid and giant cell in 16, 10, 4 and 1 cases.
  • The overall survival rate of 1-, 3- and 5-year was 61.3% +/- 9.8%, 31.6% +/- 11.3% and 21.1% +/- 11.4% with a median survival time of 17.0 +/- 6.3 months.
  • Complete resection of the tumor was the major prognostic factor.
  • Postoperative radiotherapy of 20 - 45 Gy was able to prolong the median survival from 12.1 +/- 11.6 months of surgery alone to 26.4 +/- 22.0 months of surgery plus postoperative radiotherapy though without statistical significance (P = 0.051).
  • Postoperative CHOP chemotherapy was not shown to be beneficial.
  • CONCLUSION: Chemotherapy remains the important method of cure.
  • The survival in patients with MFHR might be improved by complete resection combined with chemotherapy or/and radiotherapy.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatectomy. Postoperative Period. Prednisone / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Splenectomy. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15312351.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Takeyoshi I, Iwanami K, Yamada T, Kawate S, Hamada K, Sunose Y, Yoshida M, Horiguchi J, Ohwada S, Sasaki A, Morishita Y: Advanced gastric cancer with peritoneal dissemination successfully treated with paclitaxel and doxifluridine: a case report. Hepatogastroenterology; 2005 Jan-Feb;52(61):322-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic examination revealed an edematous lesion with redness and a giant fold in the stomach with poor expansion.
  • The histological examination of biopsy specimens from the edematous lesion revealed signet-ring-cell carcinoma.
  • Computed tomography demonstrated a thickening of the gastric wall, severe ascites, and peritoneal dissemination in the Douglas pouch.
  • By completion of the first course of treatment, the ascites had disappeared, the tumor in the Douglas pouch had shrunk, and the thickening of the gastric wall had lessened.
  • In addition, the fold in the stomach appeared by endoscopic examination to have resumed its normal thickness, no malignant cells were detected in a biopsy, and the thymidine phosphorylase activity in the tumor tissue was two-fold greater than that before chemotherapy.
  • After three treatment courses, the number of apoptotic cells had apparently increased compared with the prechemotherapy number.
  • The only adverse drug reactions that were observed were grade 2 alopecia and grade 1 myalgia.
  • After thirteen courses of chemotherapy over the past one year, both primary and metastatic lesions seem to be regressing.
  • This case study suggests that paclitaxel plus doxifluridine therapy is effective and well-tolerated in non-resectable gastric cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Female. Floxuridine / administration & dosage. Humans. Middle Aged. Neoplasm Invasiveness. Paclitaxel / administration & dosage. Pentosyltransferases / metabolism. Peritoneum / pathology. Pyrimidine Phosphorylases

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783060.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 039LU44I5M / Floxuridine; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.- / Pyrimidine Phosphorylases; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


16. Kinkor Z, Hes O: [Pleomorphic epithelioid/clear cell malignant tumor of the uterus exhibiting both myoid and melanocytic differentiation--leiomyosarcoma or PEComa? A case report and a review of the literature]. Cesk Patol; 2007 Jul;43(3):103-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleomorphic epithelioid/clear cell malignant tumor of the uterus exhibiting both myoid and melanocytic differentiation--leiomyosarcoma or PEComa? A case report and a review of the literature].
  • [Transliterated title] Pleomorfni epiteloidni a svetlobunecný maligní tumor delohy s myoidní a melanocytární diferenciací--leiomyosarkom nebo PECom? Kazuistika a prehled literatury.
  • The neoplasm broadly invaded myometrium with no evidence of endometrial cavity involvement.
  • Microscopically, the tumor displayed solid mosaic pattern and consisted of large epithelioid cells with ample eosinophilic, finely granular cytoplasm ongoing apparent clear cell change elsewhere.
  • There was marked nuclear irregularity with numerous atypical mitotic figures and multiple bizarre giant elements dispersed throughout the lesion.
  • No obvious stigmata of tuberous sclerosis were found and a five months follow-up after chemotherapy indicated no progression of disease.
  • With some uncertainty the tumor was finally rendered as pleomorphic leiomyosarcoma with peculiar melanocytic differentiation.
  • Reviewed is the literature and discussed is the differential diagnosis.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17821838.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


17. Attanoos RL, Gibbs AR: The pathology associated with therapeutic procedures in malignant mesothelioma. Histopathology; 2004 Oct;45(4):393-7
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathology associated with therapeutic procedures in malignant mesothelioma.
  • AIMS: To describe iatrogenic pathological lesions in malignant pleural mesothelioma.
  • METHODS AND RESULTS: All cases of malignant pleural mesothelioma confirmed by antemortem pleural biopsy and undergoing post mortem examination over a 7-year period (1995-2001) formed the study group.
  • This comprised 48 malignant pleural mesotheliomas [epithelioid (n = 21), biphasic (n = 14) and sarcomatoid (n = 13)].
  • Twenty-eight of 48 (58%) had received chemical (talc) pleurodesis, 30/48 (63%) palliative localized radiotherapy, 6/48 (13%) chemotherapy, and 14/48 (30%) surgery [12/48 (26%) pleural decortication and 2/48 (4%) pleuropneumonectomy].
  • CONCLUSIONS: Talc pleurodesis induces a marked pseudosarcomatous fibroblastic proliferation which may impart a biphasic pattern to the neoplasm.
  • In more chronic cases, paucicellular fibrosis with a foreign body giant cell reaction is noted.
  • The talc is polarizable and deposited in linear fashion within the tumour.
  • Tumour nodules developing subjacent to iatrogenic wound sites were noted in 8/48 (17%) cases.
  • In 6/8 (75%) of these cases, comparative assessment of the locally irradiated subcutaneous chest wall tumour, with background pleural mesothelioma, showed no morphological difference in architectural tumour growth pattern, extent of necrosis, cytological or nuclear pleomorphism, mitotic activity or tumour immunophenotype.
  • In 2/8 (25%) cases the locally irradiated tumour showed prominent bizarre multinucleated tumour giant cells and intense mixed inflammation, a feature not seen in the background (non-irradiated) tumour.
  • All six malignant pleural mesotheliomas receiving chemotherapy appeared refractory to treatment in that chemotherapy did not appear to have any significant effect on the tumour morphology, cytonuclear pleomorphism, mitotic activity, extent of necrosis or immunophenotype.
  • In the 12 decortication specimens and two pleuropneumonectomy resections, post mortem examination identified evidence of residual malignant mesothelioma of similar morphological subtype and immunophenotype to the resected tumour.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pleurodesis. Radiotherapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Iatrogenic Disease. Talc / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15469478.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 14807-96-6 / Talc
  •  go-up   go-down


18. Choi HJ, Park IA: Fine needle aspiration cytology of metastatic choriocarcinoma presenting as a breast lump. A case report. Acta Cytol; 2004 Jan-Feb;48(1):91-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: While choriocarcinoma is a rapidly invasive, widely metastasizing malignancy, it responds well to chemotherapy, so it is important to obtain an early diagnosis.
  • CASE: A 48-year-old female presented with a cough, hemoptysis and epistaxis.
  • Chest computed tomography revealed multiple nodules in both lung fields.
  • FNAC of the breast showed a malignant tumor that had been misdiagnosed as a metastatic non-small cell carcinoma of the lung.
  • CONCLUSION: The cytologic features of choriocarcinoma are quite characteristic, with side-by-side, malignant, mononucleated cells and multinucleated giant cells corresponding to cytotrophoblasts and syncytiotrophoblasts, respectively.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Cell Nucleus / pathology. Chorionic Gonadotropin, beta Subunit, Human / blood. Cough / etiology. Cough / pathology. Diagnosis, Differential. Epistaxis / etiology. Epistaxis / pathology. Female. Giant Cells / pathology. Hemoptysis / etiology. Hemoptysis / pathology. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Pregnancy. Treatment Outcome

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14969189.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


19. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • All patients presented with a solitary mass, ranging in size from 1.8 to 12 cm (median 6.8 cm).
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Binucleated cells were common, and 6 cases contained tumor giant cells.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.
  • Tumor size may be a prognostic factor.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Chen W, Zhu H, Zhang L, Li K, Su H, Jin C, Zhou K, Bai J, Wu F, Wang Z: Primary bone malignancy: effective treatment with high-intensity focused ultrasound ablation. Radiology; 2010 Jun;255(3):967-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone malignancy: effective treatment with high-intensity focused ultrasound ablation.
  • From December 1997 to November 2004, 80 patients with a primary bone malignancy-60 with stage IIb disease and 20 with stage III disease (Enneking staging system)-were treated with US-guided high-intensity focused ultrasound ablation.
  • High-intensity focused ultrasound ablation combined with chemotherapy was performed in 62 patients with osteosarcoma, one patient with periosteal osteosarcoma, and three patients with Ewing sarcoma.
  • The remaining 14 patients had chondrosarcoma, giant cell bone cancer, periosteal sarcoma, or an unknown malignancy and were treated with high-intensity focused ultrasound ablation only.
  • Magnetic resonance (MR) imaging or computed tomography (CT), and single photon emission computed tomography (SPECT) were used to assess tumor response.
  • RESULTS: High-intensity focused ultrasound ablation guided by real-time US was performed.
  • Follow-up images demonstrated completely ablated malignant bone tumors in 69 patients and greater than 50% tumor ablation in the remaining 11 patients.
  • Among the patients with stage IIb disease, long-term survival rates were substantially improved in the 30 patients who received the full treatment-that is, complete high-intensity focused ultrasound and full cycles of chemotherapy-compared with the survival rates for the 24 patients who did not finish the chemotherapy cycles and the six patients who underwent partial ablation only.
  • CONCLUSION: US-guided high-intensity focused ultrasound ablation of malignant bone tumors is feasible and effective and eventually may be a component of limb-sparing techniques for patients with these cancers.
  • [MeSH-major] Bone Neoplasms / therapy. Ultrasonic Therapy / methods. Ultrasonography, Interventional
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Prospective Studies. Survival Rate. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2010
  • (PMID = 20501734.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Rocha LA, Rizo VH, Romañach MJ, de Almeida OP, Vargas PA: Oral metastasis of alveolar soft-part sarcoma: a case report and review of literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr;109(4):587-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alveolar soft-part sarcoma (ASPS) is a rare malignant neoplasm with uncertain histogenesis and with a distinctive morphology.
  • A 27-year-old male patient, who was under chemotherapy treatment for ASPS of the thigh, presented in our dental clinic with a painless and pedunculated nodule on the right tuber maxillae.
  • An incisional biopsy was performed and the diagnosis of metastatic ASPS was made.
  • Histologically, the tumor was characterized by a proliferation of polyhedral cells in pseudoalveolar pattern.
  • Tumor cells were large, showing granular cytoplasm, periodic acid-Schiff positive diastase-resistant intracytoplasmic material, and vesicular nuclei with prominent nucleoli.
  • Unfortunately, the patient died 2 months after the diagnosis of the oral metastasis.
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Cell Nucleolus / ultrastructure. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Diagnosis, Differential. Fatal Outcome. Gingival Diseases / diagnosis. Granuloma, Giant Cell / diagnosis. Granuloma, Pyogenic / diagnosis. Humans. Male. Muscle Neoplasms / pathology. Thigh / pathology

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20303057.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Tytherleigh MG, Birtle AJ, Cohen CE, Glynne-Jones R, Livingstone J, Gilbert J: Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour. Surgeon; 2006 Dec;4(6):378-83
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
  • BACKGROUND: The Buschke-Löwenstein tumour (BLT) or giant condyloma acuminata is a rare disease which affects the anogenital region.
  • Although histologically benign, it behaves in a malignant fashion, infiltrating the surrounding tissues.
  • The morbidity and mortality from this tumour is high, as is the risk of recurrence following treatment.
  • It lies on the continuum between the benign condylomata acuminata and squamous cell carcinoma.
  • Treatment is controversial, with topical chemotherapy, radiotherapy, immunotherapy and radical surgery all having been employed.
  • Chemoradiation remains the mainstay of treatment for anal cancers but has not been routinely employed in the management of the BLT without squamous cell carcinoma transformation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Condylomata Acuminata / therapy. Neoadjuvant Therapy. Perineum / pathology. Perineum / surgery. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Adult. Anus Neoplasms / secondary. Anus Neoplasms / therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Rectal Neoplasms / secondary. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152203.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al-Katib AM: Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines. Anticancer Drugs; 2000 Jun;11(5):385-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines.
  • For the first time, we report the effect of CA-4 against a panel of malignant human B-lymphoid cell lines [early pre-B acute lymphoblastic leukemia (Reh), diffuse large cell lymphoma (WSU-DLCL2), chronic lymphocytic leukemia (WSU-CLL) and Waldenstrom's macroglobulinemia (WSU-WM)].
  • Our results indicate, using the prodrug form of CA-4, a concentration-dependent growth inhibition in all tested cell lines, although WSU-DLCL2 was more sensitive.
  • When used against the WSU-DLCL2 cell line, this same concentration of CA-4 was completely toxic.
  • Morphological examination showed CA-4 induced the formation of giant, multinucleated cells, a phenomenon commonly found in mitotic catastrophe.
  • Based on these preliminary studies, we believe that mitotic catastrophe is the predominant mechanism by which CA-4 induces cell death rather than apoptosis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Lymphoma, B-Cell / drug therapy. Prodrugs / pharmacology. Stilbenes / pharmacology. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Annexin A5 / metabolism. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Division / drug effects. DNA, Neoplasm / drug effects. Flow Cytometry. Humans. Mitosis / drug effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10912955.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA79837; United States / NCI NIH HHS / CA / P30 CA22453-20
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Neoplasm; 0 / Prodrugs; 0 / Stilbenes; I5590ES2QZ / fosbretabulin
  •  go-up   go-down


24. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 12 males and 11 females with a median age at RT of 6.6 years (range, 2 months to 20 years).
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • Median RT dose was 45 Gy (range, 12.3 to 60 Gy) using 4 MV in 9, 1.25 MV in 8, 250 KV in 4, and 6 MV photons in 1 patient.
  • Fourteen had chemotherapy.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804994.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Nakamura H, Takeshima H, Makino K, Kuratsu J: Evaluation of residual tissues after adjuvant therapy in germ cell tumors. Pediatr Neurosurg; 2007;43(2):82-91
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of residual tissues after adjuvant therapy in germ cell tumors.
  • OBJECTIVE: Germ cell tumors are the tumors sensitive for adjuvant therapy such as radiotherapy and chemotherapy.
  • We evaluated the pathological findings of these heterogeneous tumors to determine the persistence of residual viable tumor cells after adjuvant therapy.
  • PATIENTS AND METHODS: Between 1988 and 2005, we treated 31 patients with germinoma or germinoma with syncytiotrophoblastic giant cells (STGC) and 15 patients with non-germinomatous malignant germ cell tumors (NGMGCTs).
  • RESULTS: Post-treatment, 3 group 1 and 12 group 2 patients manifested residual tumors.
  • The pathological diagnosis in group 1 patients was mature teratoma, pineal cyst, and fibrous tissue with calcification; in group 2 it was yolk sac tumor (n = 1), immature teratoma (n = 3), mature teratoma (n = 4), and necrosis or fibrous tissue (n = 4).
  • While no group 1 patients manifested tumor cells, MIB-1-positive viable tumor cells were present in resected tissues from one-third of the group 2 patients (3 immature teratomas and 1 yolk sac tumor).
  • CONCLUSION: The absence of viable tumor cells in residual tissue indicates that the combination of cisplatin-based chemo- and radiotherapy was effective in our germinoma patients.
  • On the other hand, in patients with NGMGCTs, these cells persisted despite this combination therapy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Neoplasm, Residual / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Protocols. Biopsy. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Giant Cells / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Survival Rate. Trophoblasts / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17337917.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


26. Koswig S, Budach V: [The role of radiotherapy in the treatment of bone neoplasms]. Chirurg; 2002 Dec;73(12):1174-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of radiotherapy in the treatment of bone neoplasms].
  • Primary malignant bone neoplasms are relatively rare.
  • The most common bone tumors are osteosarcoma,Ewing's sarcoma,chondrosarcoma, fibrosarcoma,malignant fibrous histiocytoma of bone, giant cell tumor, aneurysmal bone cyst and chordoma.
  • Only for the management of primary Ewing's sarcoma the radiation therapy is an essential part in the multimodal therapy concept.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Cysts, Aneurysmal / radiotherapy. Bone Cysts, Aneurysmal / surgery. Child. Child, Preschool. Chordoma / radiotherapy. Chordoma / surgery. Clinical Trials as Topic. Combined Modality Therapy. Dose Fractionation. Female. Fibrosarcoma / radiotherapy. Fibrosarcoma / surgery. Follow-Up Studies. Giant Cell Tumors / radiotherapy. Giant Cell Tumors / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Palliative Care. Postoperative Care. Radiotherapy Dosage. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12491046.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


27. Fu M, Shen JN, Huang G, Wang J, Fu QZ, Yang ZH: [Reconstruction of the hemipelvis with saddle prosthesis after excision of malignant tumors around the pelvis and acetabulum: a report of 12 cases]. Ai Zheng; 2007 Nov;26(11):1237-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction of the hemipelvis with saddle prosthesis after excision of malignant tumors around the pelvis and acetabulum: a report of 12 cases].
  • BACKGROUND & OBJECTIVE: Malignant tumors around the pelvis and acetabulum locate deeply with complex anatomic structure, meanwhile, the resection area involves the weight-loading alignment.
  • Therefore, tumor resection plus acetabular joint reconstruction is a complicated operation.
  • This study was to summarize our experience of tumor resection plus prosthesis reconstruction of the acetabular joint for this disease.
  • METHODS: Clinical data of 12 patients with malignant tumors around the pelvis and acetabulum, treated with tumor resection plus prosthesis reconstruction of the acetabular joint from 1995 to 2006, were reviewed.
  • The characteristics of the operating for this disease were analyzed in terms of preoperative preparation, operating strategy, prosthesis design, operating procedure, acetabular reconstruction, and postoperative rehabilitation.
  • RESULTS: The patients were followed for 8-86 months, with a median of 46 months.
  • Of the 4 patients with tumor relapse, 2 osteosarcoma patients died of lung metastasis at 15 months and 22 months after operation; 1 chondrosarcoma patient relapsed locally at 26 months after operation and died at 38 months after operation; 1 giant cell tumor patient relapsed locally at 13 months after operation and was treated by clearance of focal lesion, and survived tumor-freely till the end of follow-up.
  • The other 9 patients still survived tumor-freely till the end of follow-up.
  • CONCLUSIONS: Pelvic tumor resection and prosthesis reconstruction of the acetabular joint has the characteristics of difficulty and high-risk.
  • For bone tumors with relatively low malignancy, this surgical treatment is an ideal option.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Osteosarcoma / drug therapy. Osteosarcoma / secondary. Osteosarcoma / surgery. Pelvic Bones / surgery. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991325.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


28. Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ: Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther; 2001 May 1;12(7):811-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
  • Malignant gliomas are the most common primary brain tumors in adults and, with few exceptions, have a dismal prognosis despite the therapeutic use of surgery, radiation therapy, and chemotherapy.
  • Because CNS gliomas rarely metastasize, they represent an attractive target for gene therapy through local gene delivery.
  • Here we report on the use of two different fusogenic membrane glycoproteins (FMGs), the measles virus proteins F and H (MV-F and MV-H) and a mutated form of the retroviral envelope protein of the gibbon ape leukemia virus (GALV.fus), as a novel class of therapeutic transgenes in gliomas.
  • Transfection of U87 and U118 cells with MV-F and MV-H cDNA or GALV.fus cDNA led in 48 hr to massive syncytial formation followed by cell death.
  • FMG-mediated cytotoxicity in the U87 and U118 cell lines was superior to the cytotoxicity caused by transfection with HSV-tk cDNA followed by ganciclovir (GCV) treatment at all time points.
  • At high-density cell seeding, addition of tumor cells transfected with MV-F and H killed at least 1 log more cells than by HSV-tk + GCV treatment, indicating higher bystander effect.
  • The mechanism of syncytial death in cultured glioma cell lines was predominantly apoptotic.
  • Treatment of established U87 xenografts in nude mice with a combination of F and H adenoviruses at 1:1 ratio led to complete tumor regression, significantly higher antitumor effect, and prolongation of survival as compared with control animals treated with a GFP adenovirus.
  • In summary, the viral fusogenic membrane glycoproteins (GALV and the MV-F + MV-H combination) are potent therapeutic transgenes with potential utility in the gene therapy of gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / therapy. Genetic Therapy / methods. Glioma / genetics. Glioma / therapy. Viral Fusion Proteins / genetics. Viral Fusion Proteins / therapeutic use
  • [MeSH-minor] Animals. Apoptosis. Cell Fusion. Ganciclovir / pharmacology. Genetic Vectors / genetics. Giant Cells / metabolism. Giant Cells / pathology. Hemagglutinins, Viral / adverse effects. Hemagglutinins, Viral / genetics. Hemagglutinins, Viral / metabolism. Hemagglutinins, Viral / therapeutic use. Humans. Lentivirus / genetics. Leukemia Virus, Gibbon Ape / genetics. Measles virus / genetics. Membrane Glycoproteins / adverse effects. Membrane Glycoproteins / genetics. Membrane Glycoproteins / metabolism. Membrane Glycoproteins / therapeutic use. Mice. Mice, Inbred BALB C. Mice, Nude. Mutation / genetics. Neoplasm Transplantation. Thymidine Kinase / genetics. Thymidine Kinase / metabolism. Transgenes / genetics. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11339897.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 84388-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemagglutinins, Viral; 0 / Membrane Glycoproteins; 0 / Viral Fusion Proteins; 0 / hemagglutinin protein G, measles virus; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


29. Raveglia F, Mezzetti M, Panigalli T, Furia S, Giuliani L, Conforti S, Meda S: Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg; 2004 Nov;78(5):1742-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pleomorphic carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pleomorphic carcinoma is a rare epithelial malignant tumor.
  • Pulmonary pleomorphic carcinoma was introduced by the 1999 World Health Organization classification as a new peculiar type of lung carcinoma showing concurrent malignant epithelial and sarcomatoid spindle cell elements.
  • My colleagues and I report a series of patients surgically treated for pulmonary pleomorphic carcinoma to describe our experience with this malignant neoplasm.
  • Histologic diagnosis was established by using light microscopic examination and immunohistochemistry.
  • RESULTS: We postoperatively diagnosed 20 cases of pleomorphic carcinoma: 14 cases were exclusively spindle and giant-cell carcinomas, 2 cases were spindle and giant-cell carcinoma combined with adenocarcinoma, 2 were combined with squamous cell carcinoma, and 2 were combined with large cell carcinoma.
  • CONCLUSIONS: The prognosis of patients with pleomorphic carcinoma was poor, despite surgery and adjuvant chemotherapy, because of early relapse of disease.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Giant Cell / mortality. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / surgery. Cell Differentiation. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15511465.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 20
  •  go-up   go-down






Advertisement